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Abstract: Reactive oxygen and nitrogen species have cell signaling properties and are involved
in a multitude of processes beyond redox homeostasis. The peroxiredoxin (Prdx) proteins are
highly sensitive intracellular peroxidases that can coordinate cell signaling via direct reactive
species scavenging or by acting as a redox sensor that enables control of binding partner activity.
Oxidation of the peroxidatic cysteine residue of Prdx proteins are the classical post-translational
modification that has been recognized to modulate downstream signaling cascades, but increasing
evidence supports that dynamic changes to phosphorylation of Prdx proteins is also an important
determinant in redox signaling. Phosphorylation of Prdx proteins affects three-dimensional structure
and function to coordinate cell proliferation, wound healing, cell fate and lipid signaling. The advent
of large proteomic datasets has shown that there are many opportunities to understand further how
phosphorylation of Prdx proteins fit into intracellular signaling cascades in normal or malignant cells
and that more research is necessary. This review summarizes the Prdx family of proteins and details
how post-translational modification by kinases and phosphatases controls intracellular signaling.
Keywords: peroxiredoxin; Prdx; Prx; redox signaling; cell signaling; phosphorylation
1. Reactive Oxygen and Nitrogen Species in Biology
In biological systems, redox reactions can regulate intracellular levels of reactive oxygen (ROS)
and nitrogen species (RNS) to control a multitude of intracellular processes. These reactive species
include both radical and non-radical forms of ROS and RNS such as superoxide anion (O2•−), hydrogen
peroxide (H2O2), hydroxyl radical (•OH), nitric oxide (NO•), nitrogen dioxide (NO2•) and peroxynitrite
(ONOO−). The relative reactivity of these species spans several log orders of magnitude to affect
the half-life and distance traveled within the intracellular environment. The hydroxyl radical is
the most reactive of these species with a half-life on the order of 10−9 s, while H2O2 is much less
reactive in comparison with a half-life of 10−3 s [1]. Many of these reactive species were initially
regarded primarily as harmful oxidants due to the recognition that an overabundance of ROS and
RNS cause damage to DNA, proteins, lipids and carbohydrates. ROS and RNS were therefore thought
to require reduction to more inert forms in order to maintain intracellular homeostasis and prevent
pathophysiological damage. Further research has indicated that ROS and RNS play more complex
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roles in the cell with mounting evidence supporting a role for these species as mediators at lower
concentrations to control protein function and coordinate cell-signaling pathways.
There are diverse sources of ROS that emerge from several organelles within the cell.
The intracellular concentration of H2O2 has been estimated to be on the order of 1 to 10 nM [2]
under basal conditions and reach 0.5 to 0.7 µM during oxidative signaling [3]. Mitochondria have
been suggested to be a primary source of ROS due to the byproducts of oxidative phosphorylation
to produce ATP. H2O2 production has been determined to arise from as much as 1–2% of the total
oxygen utilized in isolated rat liver mitochondria during respiration [4], but there is debate as to
the magnitude [5] and the concentration of H2O2 produced in vivo [6]. Complex I [7,8] and III [9]
produce a large proportion of the ROS generated within the mitochondria as O2•− [10], which is then
reduced to H2O2 through catalytic dismutation by MnSOD [11]. The steady-state levels of O2•− have
been suggested to be relatively low [6] based on the enzymatic reaction rate (k = 109 M−1·s−1) [12]
and mitochondrial concentrations of MnSOD, which have been measured to be more than 10 µM in
isolated rat liver mitochondria [13]. Other organelles that produce ROS include peroxisomes [14], the
endoplasmic reticulum [4,15] and lysosomes [16]. The plasma membrane and cytoplasm also produce
ROS through the action of NADPH oxidase [17], prostaglandin synthase [18], lipoxygenases [19] and
xanthine oxidase [20] and transition metals [21], respectively. All of these sources contribute to both
the intracellular H2O2 load as well as the extracellular secretion of H2O2, which can reach 2 µM in
stimulated neutrophils [22].
Reactive species have a complex relationship in cancer. An overabundance of reactive species
can cause cancer initiation and drive progression and accumulation of additional DNA mutations to
support further growth (reviewed in References [23,24]). Antioxidants can, therefore, serve a protective
role to block reactive species from initiating the carcinogenic process. Suppression of reactive species
does not always impart a less malignant phenotype though. Research has shown that increasing the
intracellular concentrations of antioxidants, and antioxidant enzymes in cancer cells can similarly
drive cancer progression and more invasive characteristics [25]. Reactive species and the endogenous
signaling pathways that aid to scavenge them have been suggested to follow a U-shaped curve where
a surplus or deficiency of either can increase the risk of cancer [24,26]. Intracellular enzymatic reactive
species scavengers are therefore necessary to carefully balance the processes of proliferation and
survival against induction of cell death to maintain homeostasis and guard against malignancy.
2. Enzymatic H2O2 Scavengers
H2O2 is a particularly important reactive molecule with second messenger function.
Spatiotemporal features of the molecule enable it to possess reactivity, yet move through biological
macromolecular microenvironments intracellularly within different organelle compartments and
intercellularly to neighboring cells. Organ and cellular systems coordinate the balance of the
H2O2 through enzymatic-catalyzed reductant proteins in conjunction with the pro-oxidant sources
mentioned above to form an interconnected network that maintains homeostasis or drives oxidative
signaling. The enzymatic metabolism of H2O2 is primarily catalyzed through the action of catalase,
glutathione peroxidases (GPx) and peroxiredoxins (Prdx). While all three enzymatically metabolize
H2O2, important biochemical and biological differences exist. Insight into the basal function of the
three enzymes in vivo can be drawn from the phenotypic effects observed in gene knockout studies.
Deletion of catalase displays no overt pathological changes under basal conditions in mice, while GPx1
knockout mice were found to be smaller sized [27] and harbor a predisposition to the development of
cataracts [28–30]. These changes contrast with the more extreme pathophysiological changes that exist
upon deletion of Prdx1 and 2. Prdx1 knockout mice exhibit increased oxidative damage to DNA and
cancer incidence at various sites throughout the animal as well as shortened lifespan and hemolytic
anemia [31]. Deletion of the yeast Prdx homolog tsa1 has also been shown to have deleterious effects
such as increased oxidative damage, thermosensitivity, mutagenesis and genomic instability [32,33].
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Prdx2 knockout mice were similarly found to develop hemolytic anemia but do not show an increased
incidence of cancer [34].
3. Catalase and GPx
Catalase is localized within peroxisomes and catalyzes the decomposition of H2O2 via an iron
heme porphyrin complex [35]. A two-step mechanism is utilized where H2O2 is enzymatically
scavenged through oxidation followed by reduction of the active site heme iron. The active site
heme is initially oxidized to an oxyferryl species, which is subsequently reduced by a second H2O2
molecule to regenerate enzymatic function. Sequestration of catalase to a single organelle enables
control of peroxisomal H2O2 levels but also requires H2O2 derived from other intra- and extracellular
sources to diffuse to the peroxisome in order for catalase-dependent catalysis to occur. Catalase
exhibits a high H2O2 turnover rate [36], but sequestration in combination with other enzyme kinetic
properties, such as a Km close to 100 mM in human erythrocytes [36], yield an enzyme that is less
effective when H2O2 concentrations are low. Contrasting catalase, GPx family members are found
within several organelles. There are eight family members in the glutathione peroxidases (GPx) family
(GPx1-8). GPx1-4 and 6 utilize a selenocysteine active site and glutathione (GSH) as a co-factor to
reduce H2O2 [37,38]. GPx1 and 4 are present in most tissues, with GPx1 expression found in the
cytoplasm and mitochondria, while the phospholipid hydroperoxide reducing GPx4 is found in the
plasma membrane and cytoplasm [38]. Although GPx1 and 4 do not display true Michaelis Menten
kinetics, the second-order rate constant of the two-part catalytic cycle is in the range of 105 M−1 s−1 [38].
Gpx5 and GPx7-8 are non-selenoproteins that possess an active site cysteine residue, which harbors
decreased peroxidase activity in contrast to the other selenocysteine-containing family members [39].
These proteins have been suggested to play a redox sensor role.
4. Prdx
The Prdx family has six members (Prdx1-6) that are present in many cellular compartments.
Prdx1, 2 and 6 are located in the cytoplasm, and nucleus; Prdx3 is localized to the mitochondria;
Prdx4 is found in the endoplasmic reticulum; and Prdx5 is located in the peroxisomes, cytoplasm and
mitochondria [40]. The Prdx family have 1 or 2-cysteine (Cys)-dependent reaction mechanisms to
reduce H2O2 to water. The family is subdivided into groups classified as 2-Cys (Prdx1-4), atypical 2-Cys
(Prdx5) and 1-Cys (Prdx6) isoforms based on their structure and mechanism of action [41]. The active
site peroxidatic Cys (Cysp) is conserved among all family members at roughly 50 amino acids from the
N-terminus. The Cysp is highly reactive to H2O2 due to its surrounding amino acids, which yield rate
constants on the order of 106 to 108 M−1 s−1 [42]. Typical 2-Cys are susceptible to overoxidation of the
Cysp under conditions of heightened H2O2 concentrations, resulting in a cysteine sulfinic acid, which
can be further oxidized to a Cys sulfonic acid to cause irreversible inactivation of the enzyme [43,44].
Typical 2-Cys Prdx proteins are predisposed to overoxidation due to the presence of the C-terminal YF
motif, which associates in a loop motif with a GGLG bordering the Cysp [41,44,45]. These structural
elements can participate in the overoxidation of the catalytic cysteine; however, these motifs are not
present in mammalian Prdx5 and Prdx6, suggesting these isoforms are more resistant to H2O2 induced
sulfinylation reactions that are characteristically observed in typical 2-Cys Prdxs [40,45,46].
4.1. 2-Cys Typical Prdx
Homodimerization of Prdx proteins in a an N-terminus head to C-terminus tail fashion enables
2-Cys family members to align the Cysp to the mechanistically important resolving Cys located on
the opposing Prdx homodimerization partner near the C-terminus. Prdx1 and 2 homodimers can
associate non-covalently to form larger decameric complexes that are ordered as a pentamer of dimers
to form a doughnut-like structure [44,46]. In 2-Cys Prdx, the Cysp is oxidized by H2O2 to a sulfenic
acid moiety, which then forms a disulfide bond with the resolving Cys on the homodimerization
partner [46,47] (Figure 1). The disulfide bound dimer destabilizes decameric Prdx to cause dissociation
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of the complex [48,49]. The redox reaction cycle can be regenerated by reducing the formed homodimer
disulfide bond with Trx [50]. The Cysp can become overwhelmed in the presence of high levels of
H2O2 and become overoxidized to form Cys sulfinic or further sulfonic moieties that lack peroxidase
activity. The rate constant of the sulfenic acid form of Prdx2 with H2O2 to form the sulfinic Prdx is on
the order of 104 M−1 s−1 [51] The sulfinic form was found to be reversible via enzymatic reduction
by sulfiredoxin protein [52]. In addition to the classic Trx recycling, a second redox cycle has recently
been described for Prdx2. The sulfenic Cysp can be adducted with GSH (rate constant 500 M−1 s−1)
under physiological concentrations to protect from overoxidation and recycle with Grx1 [53].
Figure 1. Reduction of H2O2 by typical 2-Cys Prdx. H2O2 recycling by 2-Cys typical Prdx family
members involves the conversion of the peroxidatic Cys to sulfenic acid. Sulfenylated Prdx protein can
then either form a disulfide bond with the resolving Cys on the dimeric partner protein to be recycled
via Trx or GSH and Grx1 or be further oxidized to the sulfinic acid form, which can be reversed with
Srx or fully over-oxidized sulfonic acid form.
4.2. 2-Cys Atypical Prdx
The atypical Prdx5 follows a similar reaction mechanism but contrasts typical 2-Cys Prdx
by forming an intramolecular disulfide bond with the internal resolving Cys as opposed to an
intermolecular disulfide bond (Figure 2) [45,54]. Characterized by its amino acid sequence, Prdx5
differs most when compared to the other Prdx family members, with roughly only 30% sequence
identity. In comparison to other family members, Prdx5 has a broad cellular localization. Prdx5
can be found in the mitochondria, peroxisomes, cytoplasm and nucleus [45]. Both prokaryotic and
eukaryotic peroxiredoxins function to catalyze the reduction of H2O2 and ONOO- with varying
enzymatic efficiencies. Of all the Prdx family members, human Prdx5 was the first mammalian Prdx
shown to react with ONOO- with a rate constant in the range of 107 M−1 s−1. In comparison, catalytic
reduction of H2O2 by Prdx5 occurs slower, with a rate constant of roughly 105 M−1 s−1. These different
enzymatic activities suggest that when Prdx5 is localized to cellular compartments where other Prdx
family members are also present, Prdx5 may more specifically reduce ONOO- or lipid peroxides as
opposed to H2O2 [45].
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Figure 2. Reduction of H2O2 by atypical Prdx5. H2O2, ROOH and ONOO- recycling by 2-Cys atypical
Prdx5 involves the conversion of the peroxidatic Cys to sulfenic acid, which then forms a disulfide
bond with the resolving Cys to be recycled by Trx or Grx1.
4.3. 1-Cys Prdx
The 1-Cys Prdx6 protein forms homodimers but does not form a disulfide bond following
oxidation of the Cysp and instead exists in the sulfenic acid form that is reduced with GSH
(Figure 3) [55]. Prdx6 is a 1-Cys peroxiredoxin which can function as both, glutathione peroxidase
and phospholipase A2 [55]. Prdx6 differs from its other family members in that it does not utilize
thioredoxin as an electron donor and can function as a Se-independent peroxide. Prdx6 has two
primary functions, the first, as a peroxidase functioning to reduce oxidized phospholipids utilizing
amino acids Cys47, Arg132 and His39 [55]. Enzymatic activity is also present at a second site that
enables Ca2+-independent phospholipase A2 activity with the aid of Ser32, Glu140 and His26.
Figure 3. Reduction of H2O2 by Prdx6. H2O2 or ROOH recycling by 1-Cys Prdx6 involves the
conversion of the peroxidatic Cys to sulfenic acid, which then forms a disulfide bond with GSH
through the action of πGST and can be recycled back to reduced Prdx6 with another GSH.
5. The Role of Prdx in Signaling through Redox Relay
The peroxidase activity of 2-Cys Prdx has been tied to redox sensor functions to control cell
signaling pathways through protein coupling reactions [56]. Prdx2 has recently been shown to
participate in a thiol-disulfide exchange reaction with the transcription factor STAT3 to repress
transcriptional activation [57]. The highly sensitive Cysp of Prdx2, therefore, acts akin to an oxidative
receptor that transfers the oxidative signaling equivalents to a partnering target protein through a
Cys redox relay. This mechanism enables the coordination of oxidative signaling to target proteins in
the absence of high concentrations of H2O2 or highly reactive Cys elements in target proteins. Redox
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relays also exist within the cytoplasm for Prdx1 [58] and have been further investigated in larger
scale studies. CRISPR-Cas9 deletion of the cytoplasmic Prdx family members Prdx1 and 2 in HAP1
cells found that cells without Prdx1 or 2 had less oxidation of cytoplasmic protein thiols globally and
further support the importance of the redox relay hypothesis [59]. Other cellular compartments also
show redox relay actions such as in the ER for Prdx4 [60] and Gpx7 [61]. This mechanism is currently
under further exploration to determine its role in redox regulation of other previously labeled “redox
active” proteins that possess rate constants on the order of 10 to 102 M−1 s−1 [62] but reside outside
close proximity to an H2O2 generating source and within a cellular environment with abundant highly
reactive peroxidases.
6. Phosphorylation of Prdx to Promote Proliferation and Survival
Outside of oxidation of the Cysp in Prdx proteins, other factors have been described to alter
peroxidase activity and structure including local microenvironmental aspects such as pH [63],
ionic strength [64] and temperature [65]. Expression of Prdx family members in various cancers
has been shown to be altered in a number of studies (reviewed in Reference [66]), but total
protein expression is only one component to control functional signals within the intracellular
environment. Post-translational modifications can affect peroxidase activity, structure and coordinate
cell signaling through changes in Prdx activity via phosphorylation at different sites within the
protein. Phosphorylation of Prdx proteins to modulate structure and function has been established
to coordinate pro-survival and death pathways by modulating intracellular H2O2 levels within
intracellular compartments temporally. Heightened local production of H2O2 is an important step
during cell proliferation in normal and malignant cells. The reversible oxidation and inactivation
of protein tyrosine phosphatases (PTPs) enable protein tyrosine kinases (PTKs) to phosphorylate
downstream targets without PTP-dependent removal of the phosphate moiety. PTPs are more readily
targeted by H2O2 due to the enhanced reactivity of the low pKa active site cysteine residue, which
causes increased susceptibility to oxidation compared to PTKs. Cell signaling cascades, therefore,
utilize local H2O2 to coordinate signal transduction pathways to promote growth [67,68]. To develop
pools of H2O2 within different intracellular compartments, cells require not only the production of
H2O2 but the inactivation of peroxidases to drive phenotypic responses. As Prdx proteins are highly
sensitive and enzymatically responsive to low levels of H2O2, the cell has developed pathways to
inhibit peroxidase activity within the cell during cell proliferation. Suppression of Prdx1 activity by
phosphorylation has been shown to play a role during the cell cycle in two different intracellular
compartments, namely at the plasma membrane during growth factor signaling and within the nucleus
during the transition to mitosis.
6.1. Protein Tyrosine Kinase Phosphorylation of Prdx1 at the Plasma Membrane
A classic counter-example to the redox relay cell signaling coordination by Prdx described above
is provided by phosphorylation of Tyr194 on Prdx1 by Src [69]. Local inactivation of Prdx1 peroxidase
activity generates increased zonal concentrations of H2O2 through the action of Nox [70] at the
plasma membrane, which is required to drive growth factor receptor tyrosine kinase signaling [71,72].
Of importance to highlight, various growth factor receptors, Src family kinases, and NOX enzymes
are localized to the plasma membrane specifically at lipid rafts. Many studies to date have suggested
that H2O2 production by NOX1 is not sufficient alone to promote and sustain signaling [44,69]. Rather,
inactivation of Prdx1 by phosphorylation on Tyr194 causes localized and sustained accumulation
of H2O2, thereby allowing target proteins such as the Src family kinases to become oxidized [69].
To sustain further phosphorylation and inactivation of Prdx1, local accumulation of H2O2 near
lipid rafts is necessary to both simultaneously activate Src family kinases and inactivate PTPs.
H2O2-mediated inhibition of PTPs is therefore crucial for growth factor signaling as activation of PTKs
alone is not adequate to promote sufficient levels of protein tyrosine phosphorylation [69].
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Phosphorylation on Tyr194 in response to treatment of cells with EGF or PDGF displayed
isoform selectivity for Prdx1 in comparison to Prdx2 [69]. Studies showed that siRNA knockdown or
pharmacological inhibition of Src reduced the phosphorylation. The Cysp was found to be protected
from overoxidation in phosphorylated protein during co-treatment of cells with growth factor and
H2O2. In vitro studies of the phosphorylated protein found the dimeric form of the Prdx1 was present
without decamers. In vivo wound healing experiments exhibited a peak in Tyr194 phosphorylation
after 1 day, which remained for 1 week.
6.2. Cdk1-Cyclin B Phosphorylation of Prdx1 in the Nucleus
Local H2O2 accumulation through inactivation of Prdx1 by phosphorylation is also important in
the nucleus during mitosis [73]. During early mitosis, Prdx1 bound to the centrosome is inactivated by
Cdk1-cyclin B phosphorylation of Prdx1 at Thr90 to promote inactivation of the dual-specificity PTP
Cdc14B by elevated H2O2 [74]. Inactivation of Cdc14B and possibly other mitotic exit phosphatases
sensitive to inactivation by H2O2 enables active Cdk1-cyclin B to transition cells to late mitosis where
Prdx1 can be dephosphorylated to promote deactivation of Cdk1 via dephosphorylation by the now
activated Cdc14B. The importance of the centrosomal H2O2 during the transition to mitosis was
evaluated by expressing catalase fused to a centrosomal targeting sequence, which inhibited entry
into mitosis.
6.3. Phosphorylation of Prdx1 to Enhance Peroxidase Activity
While the studies above indicate post-translational modifications that serve to reduce peroxidase
activity, not all Prdx phosphorylation is repressive to enzymatic activity. The T-cell-originated protein
kinase (TOPK) can phosphorylate Prdx1 on Ser32 to enhance peroxidase activity [75]. Investigation
of proteins that bind TOPK in response to ultraviolet light B irradiation of RPMI7951 cells by mass
spectrometry identified that Prdx1 phosphorylation reduced accumulation of H2O2 in vitro and ex vivo.
In the absence of TOPK via siRNA decrease, cells were more sensitive to UVB-induced apoptosis.
Melanoma cells expressing wild-type but not Ser32Ala Prdx protein was more resistant to UVB
irradiation. Whether Prdx2 can also be phosphorylated by TOPK is unknown but may not be seen in
experiments with RPMI7951 cells, which only express high levels of Prdx1.
6.4. Prdx6 Phosphorylation to Control Phospholipase A2 Activity
Phosphorylation of Prdx6 has been found to attenuate phospholipase A2 (PLA2) activity,
which is unique to the Prdx family. As Prdx6 phosphorylation increases PLA2 activity,
phosphorylation of the protein may mirror protein overexpression seen in bladder [76], liver [77]
and lung [78–80] cancer. Within secretory organelles and lysosomes, Prdx6 has been shown to
function in lung surfactant metabolism via aiPLA2 activity [81]. Acidic calcium-independent
PLA2 (aiPLA2) functions to degrade surfactant phospholipids and aide DPPC (1-palmitoyl-2-[3H]
9,10-palmitoyl-sn-glycero-3-phosphorylcholine) synthesis through the deacylation-reacylation
pathway, by providing the required substrate, lyso-PC. Phosphorylation of Prdx6 provides an
important functional role as a PLA2; phosphorylated Prdx6 maintains activity at both acidic and
cytosolic pH [81]. Treatment of isolated rat alveolar type II cells with phorbol myristic acid (PMA) was
found to increase Prdx6 phosphorylation and aiPLA2 activity through the MAPK pathway [81]. ERK1,
ERK2, p38α, p38β2, p38γ and p38δ but not JNK, were able to phosphorylate Prdx6 in vitro and mass
spectrometry analysis revealed ERK2 specifically phosphorylated Prdx6 at Thr177. Purified Thr177Glu
Prdx6 protein exhibited 2-fold higher PLA2 activity compared to Thr177Ala protein.
Phosphorylation of Prdx6 on Thr177 was found to be critical for activation of NOX2 in pulmonary
microvascular endothelial cells (PMVEC) by angiotensin II (Ang II) or PMA [82]. Phosphorylation
of Prdx6 caused cytoplasmic to plasma membrane translocation and Prdx6−/− PMVEC displayed
dramatically decreased plasma membrane translocation of the NOX2 components Rac1 or p47phox
following Ang II stimulation. Upon treatment with the known MAPK inhibitor, U0126, Prdx6
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phosphorylation, PLA2 activity and ROS were significantly decreased. This result suggested that
MAPK activation mediates phosphorylation of Prdx6 resulting in its translocation to the cellular
membrane, whereby, PLA2 activity can function to promote NOX2 activation [82]. Whether peroxidase
activity is altered in phosphorylated Thr177 is unclear. Wu et al. suggested that peroxidase activity
was not affected in Thr177Ala Prdx6, but Chhunchha et al. have found there is a 25% reduction in
peroxidase activity [81,83]. Chhunchha et al. further determined that peroxidase-deficient C47S Prdx6
protein had 30% decreased PLA2 activity when compared to wild-type protein [83].
7. Phosphorylation of Prdx to Induce Cell Death
In addition to phosphorylation pathways that promote cell proliferation and pro-survival by
increasing H2O2 in the cell, phosphorylation of Prdx proteins has been tied to cell death. Interestingly,
Prdx1 phosphorylation at Thr90, which aids in driving the cell cycle through mitosis in the nucleus as
described above, can also be targeted by tumor suppressor proteins. The difference between activation
of survival or death pathways based on phosphorylation of the same protein at the same amino acid
highlights the importance of location and timing of Prdx phosphorylation and the possible involvement
of additional phosphorylation of Prdx1 at Thr183 to control activity. The following sections will detail
the mechanistic studies that implicate Prdx phosphorylation with death. While some examples
below highlight neurodegenerative pathways as examples of inactivation by phosphorylation, further
cancer-focused work needs to be undertaken to extend these mechanisms as both Cdk5 and LRRK2
activity have been implicated in cancer. Cdk5 activity has been noted to be involved in proliferation,
migration, invasion, metastasis, the epithelial to mesenchymal transition, the DNA damage response
and angiogenesis in many forms of human cancer (as reviewed in Reference [84]). The LRRK2 p.G2019S
activating mutation has also been associated with an increased risk of cancer [85,86].
7.1. Phosphorylation of Prdx1 by Mst1
Mammalian sterile 20–like kinase-1 (Mst1) and Mst2 have been shown to suppress tumor
formation in the liver and intestines in vivo [87–90]. Mst1 and Prdx1 have been shown to regulate
the activity of one another. Cells treated with H2O2 cause Prdx1 to bind Mst1, which was found
to promote Mst1 activation and enhance apoptosis [91]. Loss of Prdx1 was further shown to be
important for Mst1 stimulation by H2O2. In contrast, phosphorylation of the Thr90 residue of Prdx1
by Mst1 and possibly Mst2 has been described to inactivate peroxidase activity [92]. Full-length Mst1
is localized in the cytoplasm, but caspase cleavage causes nuclear translocation of the kinase [93].
Whether Mst1 inactivation of Prdx1 is cell compartment-dependent or specific to the nucleus or
cytoplasm is unknown. Mst1 can additionally phosphorylate Thr183 in the C-terminus of the Prdx1,
which may also inactivate peroxidase activity as indicated by in vitro assays with site-directed
mutagenesis engineered Thr183Asp Prdx1 purified protein [92]. Expression of Thr183Asp Prdx1
protein in Prdx1−/− mouse embryonic fibroblasts (MEFs) showed heightened levels of the DNA
damage biomarker phosphorylated Ser139 H2AX following treatment with H2O2. This finding
suggests that the inactivation of Prdx1 by Mst1 could potentially cause a positive feedback loop
whereby excess H2O2 further activates Mst1. That inactivation of Prdx1 by phosphorylation can
promote Mst1 activation, while knockdown of Prdx1 can inhibit Mst1 activity, suggests that a more
complex pattern of regulation is present that may involve both oxidation and phosphorylation.
7.2. Prdx2 Inactivation by Phosphorylation by Cdk5 Complexes
Prdx2 phosphorylation has been primarily investigated in pathological brain diseases and injury.
Mitochondrial dysfunction and excessive oxidative stress are believed to be critical facilitators of the
pathogenesis of Parkinson’s disease (PD). Neurons have oxidative metabolism systems in place, such
as Prdxs, to manage and prevent the accumulation of deleterious levels of oxidative stress but can
be overwhelmed when ROS scavengers are decreased or inactivated. In the context of PD, Prdx2
associates with a Cdk5 kinase complex via p35 or the proteolytically cleaved products of p35, p10
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and the hyper-activated p25 [94]. Cdk5/p35 and Cdk5/p25 complexes were shown to phosphorylate
Prdx2 at Thr89, resulting in a decrease in Prdx2 peroxidase activity and neuronal death in MPP+
treated cells in vitro and MPTP treated mice in vivo. Furthermore, Cdk5 activation was shown to
mediate dopaminergic (DAergic) neurodegeneration by downregulation of Prdx2 peroxidase activity
which ultimately leads to significant elevations of intracellular ROS and DAergic neuron death [94].
This observation was extended to human PD where it was demonstrated that phosphorylated Prdx2
was elevated in neurons in the soma of clinical PD patient samples [94]. Another report identified
that phosphorylation of Prdx2 by the Cdk5/p25 complex could be inhibited by expression of p10 in
SH-SY5Y cells and MPP+ treated rat cortical neurons [95]. Expression of p10 was further found to
reduce intracellular ROS in these cells. As Prdx2 was originally identified to interact with p35 via
precipitation of the p10 fragment [94], p35 seems to have a bifunctional regulatory mechanism to
regulate Prdx2-dependent cell death through phosphorylation. The ability of Cdk5 to phosphorylate
Prdx proteins was also shown to include both Thr89 Prdx2 and Thr90 Prdx1 in Alzheimer’s disease
models [96]. Cdk5-dependent phosphorylation of Prdx protein caused mitochondrial damage due to
oxidative stress induced by Aβ or glutamate.
The Cdk5-Prdx2 pathway has also been shown to cause neuronal death in ischemia models [97].
Glutamate excitotoxicity in primary cerebellar granule neurons was identified to cause increased
Thr89 phosphorylation in Prdx2 in wild-type but not p35−/− neurons. Glutamate-induced neuronal
cell death was rescued by viral expression of wild-type or Thr89Ala Prdx2 but not Thr89Glu Prdx2.
Ischemia-dependent neuronal cell death generated by 4-vessel occlusion in hippocampal CA1 neurons
could also be rescued by expression of wild-type Prdx2 but not Thr89Glu in vivo [97]. Phosphorylation
of Prdx2 exhibited reliance on Cdk5 activity as dominant negative Cdk5 could block phosphorylation.
7.3. Prdx3 Phosphorylation in the Mitochondria by LRRK2
Prdx3 is expressed in mitochondria and has been shown to be important for maintaining
mitochondria mass and membrane potential in Myc-transformed fibroblasts and breast cancer cells [98].
The debilitating effects of phosphorylation-induced repression of Prdx3 peroxidase activity have been
explored in the area of neurodegeneration. Phosphorylation of Thr146 in Prdx3 by leucine-rich repeat
kinase 2 (LRRK2) protein was associated with decreased peroxidase activity by measuring NADPH
oxidation of isolated Prdx3 [99]. The importance of the peroxidase activity of Prdx3 in the mitochondria
was demonstrated with knockdown of Prdx3 in neuronal SPx3 cells containing activated LRRK2, which
led to increased mitochondrial cytochrome c release and caspase 3 levels. These results were shown
to be relevant in postmortem brain tissue samples from patients diagnosed with Parkinson’s disease
harboring a common p.G2019S activating mutation (rs34637584:A>G) in LRRK2, which similarly
displayed heightened levels of Prdx3. This mechanism was further explored in a Drosophila model that
expressed activated kinase mutant LRRK2, where overexpression of Prdx3 rescued flies from decreased
lifespan, depletion of dopaminergic neurons and dysfunctional mitochondria in flight muscles of
flies [100]. The importance of the scavenging activity of Prdx3 was shown by pharmacologically
rescuing the dysfunctional phenotypic effects of activated kinase mutant LRRK2 in Drosophila with the
Prdx mimetic ebselen, which diminishes H2O2 and peroxynitrite.
8. Dephosphorylation of Prdx Family Members
Reports detailing the importance of interactions between kinases and Prdx family members
suggest dephosphorylation may represent an equally significant process. The absence of a Prdx
phosphate removal mechanism would require phosphorylated Prdx protein to be degraded or
sequestered for future coordination of various signaling pathways. Protein recycling through
proteasomal degradation may occur, but this would represent an energy-intensive process requiring
de novo expression of unmodified protein during signaling events. While information regarding
the dephosphorylation of Prdx family members is relatively scarce, some information is available.
The protein phosphatase PP2A has been identified to dephosphorylate Prdx1 when phosphorylated
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at Thr90, which could be blocked with okadaic acid [101]. Dephosphorylation of Prdx1 was
regulated by the peptidylprolyl cis/trans isomerase Pin1 and found to be attenuated in Pin1−/−
MEFs. The association between Pin1 and Prdx1 was enhanced in the presence of 50 µM H2O2 and
could be inhibited by pharmacologically blocking Cdk1 activity or mutation of Thr90 Prdx1 to Ala.
Further experiments found that Pin1 could also bind Prdx2, 3 and 4 but not in cell lysates containing
Thr-Pro motif mutants Thr89Ala Prdx2, Thr146Ala Prdx3 and Thr162Ala Prdx4.
Dephosphorylation of Prdx4 has also been demonstrated by Ptp1b [102]. Granulocyte
colony-stimulating factor (G-Csf) stimulation of Ptp1b-proficient MEFs increased phosphorylation
of Prdx4 over 2 h as measured by immunoblot using phosphor-Tyr antibodies from Prdx4
immunoprecipitated samples. Ptp1b−/− MEFs exhibited significantly higher levels of Prdx4
phosphorylation in the presence or absence of G-Csf stimulation when compared to Ptp1b-proficient
MEFs. It is unclear which Tyr was phosphorylated in Ptp1b−/− MEFs or the functional consequences,
but the authors suggested that the Tyr phosphorylation may decrease Prdx4 peroxidase activity.
Overall, the existence of phosphatases that dephosphorylate Prdx family members is an area that
requires further exploration.
9. Unexplored Regulatory Prdx Phosphorylation
The current state of knowledge of phosphorylation as a means to modulate Prdx function has
been relatively understudied. While biochemical details exist for modification at Ser32, Thr90, Thr183
and Tyr194 and attempts have been made to evaluate Thr18, the consequences of phosphorylation of
Prdx1 at multiple sites are unclear. Phosphorylation of Prdx1 Thr90 and Thr183 would be expected
to perform similar functions as both sites are targeted by Mst1, decrease peroxidase activity and
promote the formation of decameric complexes, but not all combinations are as straightforward.
There are questions regarding what occurs when contrasting sites are phosphorylated that cause
distinct changes to the oligomeric tertiary structure or peroxidase activity. Phosphorylation of Ser32
has been shown to enhance peroxidase activity, but whether this can exert a dominant effect to
rescue the decreased peroxidase functionality of Prdx phosphorylated at Thr90, Thr183 or Tyr194
is unknown. The general structure of a phosphorylated Thr90 or Thr183 Prdx1 decamer may also
collapse following Tyr194 phosphorylation, which has been shown to lead to homodimers of Prdx1
primarily. Multi-site phosphorylation may be precluded from occurring in some cases due to changes
in the three-dimensional protein structure that prevent sequential kinase binding from occurring,
but many other proteins have been shown to have multi-layered signal transduction cascades
of regulation. The existence of positive and negative phosphorylation feedback loops to control
post-translationally modified proteins temporally has been well documented in transcription factors,
kinases and other enzymes.
In our current era where large resource experimental datasets have become more readily available
due to technical advancements, large proteomic datasets can be mined to determine if protein
modifications are present under a myriad of conditions. Published datasets have emerged that support
existence of novel phosphorylated forms of Prdx family members. As modifications of plants have
been well described in a previous review by Liebthal et al. [103], we will instead focus on mammalian
phosphorylated Prdx residues that are conserved in humans and indicated in the PhosphoSitePlus
database. 17 separate phosphorylated species have been identified using high-throughput proteomic
techniques for Prdx1 and so far only four of the sites have been biochemically characterized (Table 1).
Residues in bold were identified in proteomic screens in cancer cells and may serve cancer-specific
functions. Prdx1 represents the most well-characterized member of the Prdx family. As detailed above,
Prdx1 can play an important role in coupling phosphorylation-based cell signaling pathways to thiol
redox-based signaling systems to control an array of processes including receptor tyrosine signaling
and cell division.
Phosphorylation of other members of the Prdx family has been less well described. There is
evidence that the cdc2-cyclin B complex is capable of phosphorylating Prdx1, 2, 3 and 4 in vitro but
Antioxidants 2019, 8, 29 11 of 22
cell compartmentalization concerns were suggested by the authors to preclude Prdx3 and 4 from the
likelihood of interacting with Cdk proteins [123]. While Cdk-dependent phosphorylation of Prdx
has been more comprehensively detailed for Prdx1, evidence of Prdx2 targeting by Cdk5/p35 and
Cdk5/p25 complexes was described to reduce peroxidase activity and cause neuronal death in a
toxin-induced model of Parkinson’s disease [94]. Alignment of the protein sequence of Prdx1 and
Prdx2 shows a high degree of similarity between the two proteins with 77% identical residues and
overlap of several prospective Prdx2 phosphorylation sites, namely, Thr18, Ser31, Thr89, Tyr115,
Thr182, Tyr193 and Ser195. As characterization has been performed for the Prdx1 homologs Ser32,
Thr90, Thr183, and Tyr194, it is possible that phosphorylation of Prdx2 at these sites similarly alters
structure and function as seen for Thr89 in Prdx2 and Thr90 in Prdx1. It is unknown whether these
sites have divergent kinetics, kinase specificity or intracellular compartmental or phenotypic effects.
In total, 13 phosphorylation sites that have been identified in Prdx2 in proteomic studies and only
Thr89 has been characterized (Table 2).
Table 1. Phosphorylation of Prdx1 can increase or decrease peroxidase activity to coordinate cell
signaling. Phosphorylation sites that correspond to human Prdx1 in biochemical assays and proteomic
studies are referenced are indicated. Phosphorylation sites that have been identified in proteomic
screens in cancer models are in bold.
Prdx1 Residue Effect Biochemical AssayReferences
Proteomic Dataset
References
Thr18 Function unknown [92] [104,105]
Ser30 Function unknown [106–111]
Ser32 Enhanced peroxidase activity [75] [106–120]
Tyr34 Function unknown [118,121]
Ser77 Function unknown [122]
Ser80 Function unknown [122]
Thr90 Decreased peroxidase activity [73,74,92,96,123] [107]
Ser106 Function unknown [105,124]
Thr111 Function unknown [92] [104,105]
Tyr116 Function unknown [105,118,125]
Ser126 Function unknown [104,119,126]
Thr156 Function unknown [92]
Thr166 Function unknown [105]
Ser181 Function unknown [107,119,127–129]
Thr183 Decreased peroxidase activity [92] [107,127,130]
Tyr194 Decreased peroxidase activity [69] [131–136]
Ser196 Function unknown [116]
Table 2. Phosphorylation of Prdx2 can decrease peroxidase activity to coordinate cell signaling.
Phosphorylation sites that correspond to human Prdx2 in biochemical assays and proteomic studies
are referenced are indicated. Phosphorylation sites that have been identified in proteomic screens in
cancer models are in bold.
Prdx2 Residue Effect Biochemical AssayReferences
Proteomic Dataset
References
Ser3 Function unknown [137]
Thr18 Function unknown [105]
Ser31 Function unknown [111,115,116,119]
Thr89 Decreased peroxidase activity [94–97] [138]
Ser112 Function unknown [105,115,116,119,126,139,140]
Tyr115 Function unknown [118,141]
Thr120 Function unknown [111,119,140]
Tyr126 Function unknown [140]
Thr142 Function unknown [105,142,143]
Ser151 Function unknown [104,111]
Thr182 Function unknown [115]
Tyr193 Function unknown [133–136,144]
Ser195 Function unknown [144]
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In comparison to Prdx1 and 2, the number of phosphorylation sites present in large datasets is
less abundant for the rest of the protein family. Delineation of the effects of phosphorylation of Prdx3
for Thr146 in LRRK2 kinase mutant cells and flies has been described and suggests phosphorylation is
a mechanism utilized to alter peroxidase activity, but other sites have yet to be studied [98,100]. Thr146
of Prdx3 aligns with Thr90 and Thr89 of Prdx1 and Prdx2, respectively, which both have also been
characterized to reduce peroxidase activity and may be expected to additionally promote the formation
of larger oligomeric complexes upon phosphorylation (Figure 4). Prdx3 phosphorylation has been
observed at eight sites, but interestingly, Thr146 has not yet been observed in large proteomic screens
(Table 3). General exploration of the effects of phosphorylation on Prdx4 and 5 is lacking and studies
have yet to characterize the peroxidase activity or oligomeric structural results of this modification.
Proteomic data is the only resource that describes the intracellular phosphorylation of these proteins
(Tables 4 and 5). The number of phosphorylation sites for these proteins is six and five for Prdx4 and 5,
respectively. Phosphorylation of Prdx5 on Thr97 or Ser101 of the full-length unprocessed protein (Thr45
and Ser49 of the processed form) is likely to influence peroxidase activity as these residues surround
the peroxidatic Cys48 residue. Phosphorylation of the final member of the Prdx family, Prdx6, has
been described on Thr177 to elevate its aiPLA2 activity but peroxidase specific phosphorylation sites
have not yet been detailed. Six phosphorylation sites of Prdx6 have been described in large proteomic
datasets (Table 6). Tyr89 is the only Tyr residue present in Prdx6 that was detected to be phosphorylated.
Two-dimensional electrophoresis followed by mass spectrometry conducted on Bax inhibitor-1 (bi-1)+/+
and bi-1−/− mice found that Tyr phosphorylation was increased in bi-1−/− liver, brain, heart, lung and
kidney tissues [145]. The identity and functional consequences of the Tyr phosphorylation site or sites
within Prdx6 that were elevated in the knockout mice were not determined, but Tyr89 is potentially
the site of interest. Tyr89 Prdx6 may also be phosphorylated in the dorsal striatum of midkine (Mk)
knockout mice in cocaine conditioned place preference experiments [146].
Figure 4. 2-Cys Prdx alignment of observed phosphorylation sites. Alignment of the 2-Cys Prdx family
members. Phosphorylation sites that have been characterized are highlighted in pink, uncharacterized
sites that have been identified in proteomic studies are highlighted in green and sites that are aligned
with characterized phosphorylation sites are highlighted in blue.
Antioxidants 2019, 8, 29 13 of 22
Table 3. Phosphorylation of Prdx3 can decrease peroxidase activity to coordinate cell signaling.
Phosphorylation sites that correspond to human Prdx3 in biochemical assays and proteomic studies
are referenced are indicated. Phosphorylation sites that have been identified in proteomic screens in
cancer models are in bold.
Prdx3 Residue Effect Biochemical AssayReferences
Proteomic Dataset
References
Tyr71 Function unknown [125]
Ser86 Function unknown [105,119]
Thr146 Decreased peroxidase activity [99,100]
Tyr172 Function unknown [118]
Ser179 Function unknown [105,119]
Ser199 Function unknown [104,127]
Thr234 Function unknown [107,115]
Ser237 Function unknown [107,119,147]
Ser243 Function unknown [110,147]
Table 4. Phosphorylation sites that correspond to human Prdx4 in proteomic studies are referenced
are indicated.
Prdx4 Residue Effect Proteomic Dataset References
Ser68 Function unknown [115]
Ser82 Function unknown [148]
Thr91 Function unknown [148]
Tyr188 Function unknown [118]
Tyr191 Function unknown [118]
Tyr266 Function unknown [149]
Table 5. Phosphorylation sites that correspond to human Prdx5 in proteomic studies are referenced are
indicated. Phosphorylation sites that have been identified in proteomic screens in cancer models are
in bold.
Prdx5 Residue Effect Proteomic Dataset References
Thr97 Function unknown [105,107,116,119,150,151]
Ser101 Function unknown [105,119]
Ser168 Function unknown [108,112]
Ser171 Function unknown [111,150]
Ser182 Function unknown [105,112,116,119]
Table 6. Phosphorylation of Prdx6 can increase calcium-independent phospholipase A2 activity to
coordinate cell signaling. Phosphorylation sites that correspond to human Prdx6 in biochemical assays
and proteomic studies are referenced are indicated. Phosphorylation sites that have been identified in
proteomic screens in cancer models are in bold.
Prdx6 Residue Effect Biochemical AssayReferences Proteomic Dataset References
Ser32 Function unknown [111]
Thr44 Function unknown [105,114,116,119,126,128,140,152–157]
Tyr89 Function unknown [107,111,131]






Ser186 Function unknown [105,110,154]
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10. Conclusions and Future Directions
The highly sensitive peroxidatic cysteine thiol of Prdx proteins makes them well suited to sense
and control cell signaling due to minor changes in H2O2, ROOH and ONOO− concentration within
multiple cellular organelles. Research efforts have therefore primarily focused on how oxidation of
the peroxidatic Cys perturbs cell signaling. While there are many important unrealized details and
properties of Prdx oxidation that remain, the effects of other forms of post-translational modifications
to Prdx proteins represent another exciting area of exploration. Dynamic changes to oxidation,
phosphorylation and other forms of post-translation modifications can change three-dimensional
structure and function of Prdx proteins to coordinate the various processes outlined above. In addition,
control of Prdx through phosphorylation further integrates redox and signaling cascades. Inactivating
phosphorylations of Prdx proteins likely prevent Prdx redox relay reactions as the peroxidatic Cys loses
peroxidase activity. Prdx phosphorylation cascades would thus enable attenuation of Prdx-dependent
oxidative equivalent transfer to partner proteins and inhibit redox signaling. The role of peroxidase
activating phosphorylation sites such as Ser32 of Prdx1 on redox relays is also unknown but may
perhaps oppose peroxidase inactivating phosphorylation sites.
Post-translational modifications of Prdx family members have been identified to play a significant
role in several signaling cascades, but there remains to be a complete understanding of the function
of several putative sites in many family members. The introduction of phosphomimetic and
non-phosphorylatable mutants via genomic editing through systems such as CRISPR/Cas9 would be
useful to determine the functional consequences of Prdx phosphorylation in normal non-transformed
cells as well as cancer cells. Candidate phosphorylation sites to be studied further could be identified
from proteomic screens in cancer cells such as those indicated in bold in Tables 1–6 above. Several sites
have been found in multiple proteomic screens for Prdx1 (Ser32, Ser126 and Tyr194), Prdx2 (Ser112) and
Prdx6 (Thr44) and more than half have yet to be characterized. Biochemical evaluations on putative
phosphorylation sites that have already been performed have shown changes to phosphorylation
sites that can increase or decrease peroxidase activity, in the case of Prdx1 Ser32 or Prdx1 Tyr194,
respectively. Prdx peroxidase activity may, therefore, play an intricate role in cancer that could be
dependent on the oncogenic driver, cell type or cancer stage. Functional studies in these systems may
yield valuable information that helps to better understand the role of phosphorylation in Prdx biology
and cancer. Extensions into in vivo models would further develop phosphorylation of Prdx from a
systems biology perspective.
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